Covance and LabCorp open a new R&D center to pool their expertise

Covance's Herman Scholtz

Covance, recently acquired by testing giant LabCorp ($LH), has opened a new, expanded clinical research unit in Texas, pairing space for trials alongside a planned patient-service center operated by its parent company.

The new operation is in the same building as Covance's previous Dallas outpost, adding 28 beds to the prior unit's 72-patient capacity. The expanded facility is about 55,000 square feet, replete with an on-site pharmacy, space for specialized ophthalmology and diabetes tests, and 5 manufacturing suites, Covance said. The site employs 75 people and will eventually host about 120, according to the company.

The expansion also includes space for a LabCorp-run service center, which will educate study volunteers on all the combined company has to offer.

LabCorp's $6 billion acquisition of Covance, closed this year, was designed to link its expertise in real-world diagnostic testing with the CRO's capacity in clinical trials, creating an end-to-end offering. Now, installing a patient-service center at the clinical research unit is an effort to bridge the gap between clinical development and diagnostics, the company said.

"We have invested in a highly customized facility designed to facilitate the safety and quality of our studies and to enhance our clients' and volunteers' experience," Covance Vice President Herman Scholtz said in a statement. "In addition, we are excited about the unique opportunity to educate patients about our clinical trials and complement our local patient recruitment capabilities through the future LabCorp patient-service center."

- read the statement

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.